Novartis’ generics and biosimilars division, Sandoz, has launched the second edition of its Healthcare Access Challenge (Hack), the company has announced. more


Data and analytics company, GlobalData, has revealed that it believes new launches into the epinephrine injection device market will have the potential to completely transform the space. more


The European Medicines Agency (EMA) has accepted for regulatory review the marketing authorisation applications for biosimilars to AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab) from Sandoz more


The reference product is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant. more